U.S. Pharma Stock News

Why Douglas Dynamics (PLOW) is back on investors' radar Douglas Dynamics (PLOW) has drawn fresh attention after reporting fourth quarter 2025 earnings, issuing net sales guidance for 2026 between US$710 million and US$760 million, and affirming its quarterly dividend. See our latest analysis for Douglas Dynamics. The latest earnings release, 2026 net sales guidance and dividend affirmation come after a strong run in the shares, with a 30 day share price return of 24.44% and a 1 year total...

EPR Properties (NYSE:EPR) announced the retirement of Chief Investment Officer Gregory Zimmerman. Benjamin Fox has been appointed as the new CIO as part of the leadership transition. The company recently completed acquisitions in experiential real estate assets. EPR also approved a 5.1% dividend increase. EPR Properties, trading at $59.94, operates in the experiential net lease space. Its recent moves come after multi year share returns of 82.4% over 3 years and 73.6% over 5 years. In the...

Wondering whether DXC Technology at around US$12.19 is starting to look like a bargain or a value trap? This article walks through what the numbers actually say about the stock. The share price has had a mixed run, with a 2.9% return over the last 7 days, a 15.5% decline over 30 days, a 13.4% decline year to date, and a 32.7% decline over the past year. Over longer periods, the 3 year and 5 year returns sit at declines of 57.2% and 56.5% respectively. These moves have kept DXC Technology on...

If you are wondering whether Avnet at around US$64.98 is still offering value or starting to look fully priced, you are asking the right question for a stock that gets a lot of attention from value focused investors. The share price has been active recently, with a 3.4% decline over the last 7 days, a 4.2% return over 30 days, and longer term returns of 31.7% year to date, 35.8% over 1 year, 55.2% over 3 years, and 87.7% over 5 years. Recent coverage of Avnet has centered on its role as a...

DRDGOLD is progressing its Vision 2028 initiative, focused on infrastructure upgrades and operational improvements across its tailings operations. The company is moving ahead with plans to link processing plants and restart deposition at key tailings storage facilities. These developments are intended to support longer term operating plans and more efficient use of existing assets. For investors watching NYSE:DRD, the Vision 2028 work sits against a share price of $38.32 and multi year...

Multiple law firms have filed class action lawsuits against Richtech Robotics (NasdaqCM:RR) alleging the company misled investors about its relationship with Microsoft. The suits claim Richtech described a collaborative and commercial partnership with Microsoft, while Microsoft has reportedly denied having a commercial relationship. Investors are focusing on potential disclosure issues, legal exposure, and the impact of these claims on Richtech's credibility and future capital...

Carter's (NYSE:CRI) has reported its first year over year revenue growth since 2021, supported by stronger retail sales and demand creation efforts. The company plans to close about 150 lower margin stores by 2028 while expanding higher priced product assortments for Gen Z and Millennial families. Carter's is also putting more emphasis on direct to consumer channels as it adjusts to changing shopping habits and cost pressures. Carter's shares recently closed at $34.95, with the stock down...

Itron (NasdaqGS:ITRI) has completed a $700 million offering of convertible senior notes. The offering follows the company’s fourth quarter results, which were described as robust and above expectations. The transaction adds a sizable pool of capital that can influence Itron’s balance sheet and future investment decisions. Itron focuses on technology and services that help utilities and cities manage energy, water, and smart infrastructure. For investors watching the broader push toward grid...

The J. M. Smucker Company recently reported fiscal 2026 third-quarter results showing higher net sales of US$2,339.4 million but a larger net loss of US$724.2 million, alongside slightly narrowed full-year net sales guidance of 3.5% to 4.0% growth and projected diluted EPS in the range of US$1.89 to US$1.39 loss. At the same time, Smucker moved to strengthen its governance and product portfolio by adding two financially experienced independent directors following engagement with Elliott...

If you are wondering whether Supernus Pharmaceuticals at around US$55.09 is still offering value after its recent run, you are not alone. The stock has posted returns of 8.7% over the past 7 days, 14.4% over 30 days, 11.4% year to date and 73.6% over 1 year, with longer term returns of 43.5% over 3 years and 116.0% over 5 years. These moves sit against a backdrop of continuing interest in Supernus Pharmaceuticals as a neurology focused drug maker. Investors are paying close attention to how...

Danaos (DAC) has just filed an omnibus shelf registration, covering potential offerings of common and preferred stock, debt securities, warrants and other instruments, a move that gives management broad future financing flexibility. See our latest analysis for Danaos. The shelf registration comes after a strong run in the shares, with a 7 day share price return of 8.95% and a year to date share price return of 24.18%. The 1 year total shareholder return of 58.92% and 5 year total shareholder...

If you are wondering whether V2X at around US$70.97 is still offering value or already pricing in a lot of optimism, you are not alone. The stock has returned 4.5% over the last 7 days, 3.1% over the last month, 27.7% year to date and 55.0% over the past year, which naturally raises questions about what is already baked into the current price. Recent coverage has focused on V2X as a capital goods company listed on the NYSE under the ticker VVX. Investors are paying close attention to how it...

If you are looking at Medical Properties Trust and wondering whether the current share price reflects its underlying worth, you are not alone. The stock closed at US$5.65 recently, with returns of 12.5% over the last 30 days, 11.2% year to date and 4.4% over the past year, set against longer term 3 year and 5 year returns of 28.9% and 60.3% declines. Recent headlines around Medical Properties Trust have focused on its balance sheet, portfolio repositioning and how it is responding to a...

CareTrust REIT (NYSE:CTRE) has moved into the UK healthcare real estate market through the acquisition of Care REIT plc. The transaction expands CareTrust REIT's portfolio and marks its first international platform outside the US. The company has also scaled its structured finance activities alongside large portfolio acquisitions. CareTrust REIT is taking a bigger swing with this UK entry, adding a new geography on top of its existing US footprint. The stock last closed at $40.89, with a 1...

Winnebago Industries (NYSE:WGO) is working through persistent RV industry headwinds as sales have fallen over the past two years. Despite reporting revenue growth, the company has seen profitability weaken, pointing to rising pressure on its core business. This combination of softer sales trends and thinner margins is drawing attention to deeper challenges across the recreational vehicle sector. For you as an investor, Winnebago sits at the intersection of discretionary spending and outdoor...

In February 2026, Tronox Holdings plc reported fourth-quarter 2025 sales of US$730 million and a net loss of US$176 million, with full-year 2025 sales of US$2.90 billion and a net loss of US$470 million, before subsequently filing an omnibus shelf registration for ordinary shares, preference shares, and debt securities. The combination of widening losses and a new universal shelf registration highlights Tronox’s need for financial flexibility at a time of rising earnings pressure and...

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...

Hawaiian Electric Industries reported full-year 2025 revenue of US$3.09 billion, down slightly from US$3.22 billion in 2024, while swinging from a very large net loss to net income of US$123.12 million, or US$0.71 in basic and diluted earnings per share from continuing operations. The earnings rebound coincided with progress on Maui wildfire-related settlements, funded by insurance, and regulatory approval of a multi-year wildfire safety plan that supports both risk reduction and grid...

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...